AAAAAA

   
Results: 1-12 |
Results: 12
BIODEGRADABILITY OF BIODIESEL IN THE AQUATIC ENVIRONMENT
Authors: ZHANG X PETERSON C REECE D HAWS R MOLLER G
Citation: X. Zhang et al., BIODEGRADABILITY OF BIODIESEL IN THE AQUATIC ENVIRONMENT, Transactions of the ASAE, 41(5), 1998, pp. 1423-1430
SYNTHETIC SOLDIERS
Authors: KARR CR REECE D FRANCESCHINI R
Citation: Cr. Karr et al., SYNTHETIC SOLDIERS, IEEE spectrum, 34(3), 1997, pp. 39
A RANDOMIZED PHASE-II STUDY OF BB-10010 - A VARIANT OF HUMAN MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA FOR PATIENTS RECEIVING HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE FOR MALIGNANT-LYMPHOMA AND BREAST-CANCER
Authors: BERNSTEIN SH EAVES CJ HERZIG R FAY J LYNCH J PHILLIPS GL CHRISTIANSEN N REECE D ERICSON S STEPHAN M KOVALSKY M HAWKINS K RASMUSSEN H DEVOS A HERZIG GP
Citation: Sh. Bernstein et al., A RANDOMIZED PHASE-II STUDY OF BB-10010 - A VARIANT OF HUMAN MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA FOR PATIENTS RECEIVING HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE FOR MALIGNANT-LYMPHOMA AND BREAST-CANCER, British Journal of Haematology, 99(4), 1997, pp. 888-895
A RANDOMIZED PHASE-II STUDY OF BB-10010 - A VARIANT OF HUMAN MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA (MIP-1-ALPHA) FOR PATIENTS RECEIVING HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE FOR MALIGNANT-LYMPHOMA AND BREAST-CANCER
Authors: BERNSTEIN SH EAVES CJ HERZIG R FAY J LYNCH J PHILLIPS GL CHRISTIANSEN N REECE D ERICSON S STEPHAN M KOVALSKY M HAWKINS K RASMUSSEN H DEVOS A HERZIG GP
Citation: Sh. Bernstein et al., A RANDOMIZED PHASE-II STUDY OF BB-10010 - A VARIANT OF HUMAN MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA (MIP-1-ALPHA) FOR PATIENTS RECEIVING HIGH-DOSE ETOPOSIDE AND CYCLOPHOSPHAMIDE FOR MALIGNANT-LYMPHOMA AND BREAST-CANCER, Blood, 90(10), 1997, pp. 3543-3543
USE OF G-CSF-PRIMED, DELAYED BONE-MARROW (BM) HARVEST AS A SOURCE OF HEMATOPOIETIC STEM-CELLS (HSC) FOR ALLOGENEIC STEM-CELL TRANSPLANTATION (SCT)
Authors: HALE G REECE D VANZANT G BRYSON S DAVEY D MARSHALL K MUNN R NATH R PHILLIPS G
Citation: G. Hale et al., USE OF G-CSF-PRIMED, DELAYED BONE-MARROW (BM) HARVEST AS A SOURCE OF HEMATOPOIETIC STEM-CELLS (HSC) FOR ALLOGENEIC STEM-CELL TRANSPLANTATION (SCT), Blood, 90(10), 1997, pp. 4214-4214
PROPHYLAXIS OF CANDIDIASIS IN PATIENTS WITH LEUKEMIA AND BONE-MARROW TRANSPLANTS
Authors: EPSTEIN JB RANSIER A LUNN R CHIN E JACOBSON JJ LE N REECE D
Citation: Jb. Epstein et al., PROPHYLAXIS OF CANDIDIASIS IN PATIENTS WITH LEUKEMIA AND BONE-MARROW TRANSPLANTS, Oral surgery, oral medicine, oral pathology, oral radiology and endodontics, 81(3), 1996, pp. 291-296
ACYCLOVIR PROPHYLAXIS OF ORAL HERPES-VIRUS DURING BONE-MARROW TRANSPLANTATION
Authors: EPSTEIN JB RANSIER A SHERLOCK CH SPINELLI JJ REECE D
Citation: Jb. Epstein et al., ACYCLOVIR PROPHYLAXIS OF ORAL HERPES-VIRUS DURING BONE-MARROW TRANSPLANTATION, European journal of cancer. Part B, Oral oncology, 32(3), 1996, pp. 158-162
EMISSIONS CHARACTERISTICS OF ETHYL AND METHYL-ESTER OF RAPESEED OIL COMPARED WITH LOW-SULFUR DIESEL CONTROL FUEL IN A CHASSIS DYNAMOMETER TEST OF A PICKUP TRUCK
Authors: PETERSON C REECE D
Citation: C. Peterson et D. Reece, EMISSIONS CHARACTERISTICS OF ETHYL AND METHYL-ESTER OF RAPESEED OIL COMPARED WITH LOW-SULFUR DIESEL CONTROL FUEL IN A CHASSIS DYNAMOMETER TEST OF A PICKUP TRUCK, Transactions of the ASAE, 39(3), 1996, pp. 805-816
SHOULD HIGH-RISK PATIENTS WITH HODGKINS-DISEASE BE SINGLED OUT FOR HEAVIER THERAPEUTIC REGIMENS WHILE LOW-RISK PATIENTS ARE SPARED SUCH THERAPIES
Authors: REECE D
Citation: D. Reece, SHOULD HIGH-RISK PATIENTS WITH HODGKINS-DISEASE BE SINGLED OUT FOR HEAVIER THERAPEUTIC REGIMENS WHILE LOW-RISK PATIENTS ARE SPARED SUCH THERAPIES, Leukemia & lymphoma, 15, 1995, pp. 19-21
EARLY AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN THE TREATMENT OF HODGKINS-DISEASE
Authors: REECE D
Citation: D. Reece, EARLY AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN THE TREATMENT OF HODGKINS-DISEASE, Leukemia & lymphoma, 15, 1995, pp. 55-57
A PRELIMINARY-ANALYSIS OF INTENSIFIED CONDITIONING (IC) FOLLOWED BY TRANSPLANTATION OF ALLOGENEIC BONE-MARROW (ALLOBMT) DEPLETED OF CD3-GRADIENT MAGNETIC SEPARATION (HGMS) IN PATIENTS (PTS) RECEIVING UNRELATEDDONOR (UD) GRAFTS( CELLS USING HIGH)
Authors: REECE D THOMAS T LANSDORP P BARNETT M NANTEL S SUTHERLAND H SPINELLI J SHEPHERD J KLINGEMANN H PHILLIPS G
Citation: D. Reece et al., A PRELIMINARY-ANALYSIS OF INTENSIFIED CONDITIONING (IC) FOLLOWED BY TRANSPLANTATION OF ALLOGENEIC BONE-MARROW (ALLOBMT) DEPLETED OF CD3-GRADIENT MAGNETIC SEPARATION (HGMS) IN PATIENTS (PTS) RECEIVING UNRELATEDDONOR (UD) GRAFTS( CELLS USING HIGH), Blood, 84(10), 1994, pp. 10000342-10000342
DELAYED COMPLICATIONS OF VOLUNTEER UNRELATED DONOR BONE-MARROW TRANSPLANTATION (VUD-BMT)
Authors: FUNG H BARNETT M REECE D KLINGEMANN H SHEPHERD J NANTEL S SUTHERLAND H SPINELLI J PHILLIPS G
Citation: H. Fung et al., DELAYED COMPLICATIONS OF VOLUNTEER UNRELATED DONOR BONE-MARROW TRANSPLANTATION (VUD-BMT), Blood, 84(10), 1994, pp. 10000492-10000492
Risultati: 1-12 |